The COVID-19 | alex ko

The COVID- 19 Technology Access Pool( C- valve), amulti-stakeholder cooperation to grease sharing of intellectual property( IP), knowledge and inventions has blazoned three new licensing agreements acquired through the Medicines Patent Pool( MPP). The agreements include the following licenses to transfer know- style, accoutrements and clinical data demanded in different countries
Medigen Vaccine Biologics Corp, the first private manufacturer, is offering its patent and know- how for a COVID- 19 vaccine that has seen further than three million boluses administered across seven countries. It's the first time that a vaccine manufacturer is using the WHO C- valve model- a palm- palm occasion for the manufacturer, donors of the technology and, most importantly, cases in need around the world. The agreement will enable licensing of IP easing technology transfer and staff training.
Spanish National Research Council( CSIC) is participating a alternate license for a COVID- 19 vaccine prototype. The agreement includes factory visits and training, direct backing and ongoing discussion with philanthropist manufacturers, including on quality and nonsupervisory matters.
The University of Chile is participating its technology for a COVID- 19 assay for quantification of negativing antibodies.
C- valve was launched in May 2020 by the WHO and the Government of Costa Rica with the support of 44 Member States, UN Development Programme, Unitaid, UNAIDS, and enforcing mates similar as MPP. It works under the principles of the Solidarity call to action and was designed to serve as a platform for inventors of COVID- 19 rectifiers, diagnostics, vaccines and other health products to freely partake their intellectual property, knowledge, and data to accelerate technological invention and expand global product capacity.
C- valve was conceded as an important tool in the 2021 “ Original product Resolution ” to grease sustainable access to quality- assured, safe, effective and affordable drugs and other health technologies. likewise, it has played an important part in raising mindfulness of the part of technology and knowledge sharing and access- acquainted voluntary licensing.
“ COVID- 19 is then to stay, and the world will continue to need tools to help it, test for it and treat it, ” said Dr Tedros Adhanom Ghebreyesus, WHO Director- General. “ Through C- valve, WHO and our mates are committed to making those tools accessible to everyone, far and wide. I'm thankful to the leadership shown by those license holders who have contributed technology. ”
Charles Gore, Executive Director of the Medicines Patent Pool said “ Access to essential drugs and health technologies needs to remain a top precedence on the global health docket. We compliment Medigen Vaccine Biologics Corp, CSIC and the University of Chile for empowering their products to MPP and hope it'll shoot an important communication to other originators around the world to enter into farther licence agreements under the aegis of C- valve. ”
During the height of the COVID- 19 epidemic only two public health R&D Institutes-- the Spanish National Research Council( CSIC) and the US National Institute of Health( NIH) decided to partake their crucial COVID- 19 technologies with C- valve.
Addition of the three new licenses now provides an important boost to the overall trouble. The new licenses are global, transparent andnon-exclusive to all manufacturers and are accessible on the C- valve website. Importantly, the first license, on a serological test, redounded in a sub license to Biotech Africa from CSIC to develop their individual technology.
C- valve has also established a Technology Access Pool database that provides a searchable depository. With a principle of translucency, this intimately available database will support collaboration and will link to other data participating platforms where clinical, nonsupervisory, patent, and manufacturers data is available for named technologies. WHO is preparing to partake findings of the review of C- valve and a proposed model for an evolved technology access pool. Stakeholders will have an occasion to give commentary on a conception paper including the process and timelines for its perpetration.
quotations from the associations subscribing new C- valve licenses
Charles Chen, CEO of Medigen Vaccine BiologicsCorp. stated," We believe that the most effective response to a epidemic must be embedded in solidarity, cooperation, and collaborative global trouble. By joining the C- valve action, we're furnishing indifferent access to our vaccine technology. It underscores our commitment to insure that vaccines reach all corners of the globe, leaving no bone before. This isn't just about COVID- 19, it's about setting a precedent for unborn global health challenges. By demonstrating our commitment to open wisdom and collaborative strategies. We hope to inspire other associations to follow suit. To all those that trusted, shared, banded , and supported us, thank you! For without you, we couldn't make this C- valve action possible. ”
University of Chile Rector, ProfessorDr. Rosa Devés Alessandri, said, “ For the University of Chile, the achievement of our scientists, is a source of pride and an stimulant for the advancement of biomedical exploration in our country. It shows how excellent exploration carried out internationally has the capacity to offer results with a high social impact in the field of health. We thank all the organisations that have made it possible for the University of Chile to contribute to global health".
Eloisa del Pino, President of CSIC said ‘ This licensing agreement with C- valve opens the possibility of chancing mates in third countries to advance clinical trials with this vaccine as a unborn volition to certified COVID vaccine options worldwide, especially in resource-poor countries. ”
About C- valve
C- valve was launched in 2020 by the WHO Director- General and the President of Costa Rica, and supported by 44 Member States, to grease timely, indifferent and affordable access to COVID- 19 health products through transparent, public health acquainted,non-exclusive and broad licensing agreements.
WHO specialized brigades support by furnishing assessment of technologies to technology givers and receivers. This includes the lately launched WHO- Unitaid briefing document to support how to navigate interfaces between public health and intellectual property.
About MPP
The Medicines Patent Pool( MPP) is a United Nations- backed public health organisation working to increase access to and grease the development of life- saving drugs for low- and middle- income countries. Through its innovative business model, MPP mates with civil society, governments, transnational organisations, assiduity, patient groups, and other stakeholders to prioritise and certify demanded drugs and pool intellectual property to encourage general manufacture and the development of new phrasings.